5-ALA treatment increases intracellular heme levels and enhances CYP3A4 activity in genome-edited Caco-2 cells
Biochemical and Biophysical Research Communications · 2023
DOI: 10.1016/j.bbrc.2023.04.077 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2023. Verfasst von Keita Watanabe und 2 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Ritsumeikan University, 1-1-1 Noji-Higashi, Kusatsu, 525-8577, …. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP3A, Aminolevulinic Acid. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Ministry of Education, Culture, Sports, Science and Technology, Ritsumeikan University, Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
In nonclinical studies, models that can predict the metabolism of drug candidates by cytochrome P450 (CYP), including Cytochrome P450 family 3 subfamily A member 4 (CYP3A4) are helpful. CYP3A4-overexpressing human cells have been used universally to evaluate whether CYP3A4 metabolizes drug-candidate compounds. However, CYP3A4-overexpressing human cell lines are problematic because their activity levels are lower than that of in vivo human CYP3A4. Heme plays a paramount role in CYP activity. The rate-limiting step in heme biosynthesis is the generation of 5-aminolevulinic acid (5-ALA). In this study, we examined whether treatment with 5-ALA to CYP3A4-POR-UGT1A1-CES2 knockin and CES1 knockout (genome-edited) Caco-2 cells enhances CYP3A4 activity. A 7-day 5-ALA treatment increased intracellular heme levels in genome-edited Caco-2 cells without cytotoxicity. Moreover, consistent with the increase in intracellular heme content, 5-ALA treatment increased CYP3A4 activity in genome-edited Caco-2 cells. The results of this research are expected to be applied to pharmacokinetic studies using CYP-overexpressing human cells containing CYP3A4.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Ritsumeikan University, 1-1-1 Noji-Higashi, Kusatsu, 525-8577, Japan.
- Laboratory of Molecular Pharmacokinetics, College of Pharmaceutical Sciences, Ritsumeikan University, 1-1-1 Noji-Higashi, Kusatsu, 525-8577, Japan. Electronic address: negoro-r@fc.ritsumei.ac.jp.
- Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Ritsumeikan University, 1-1-1 Noji-Higashi, Kusatsu, 525-8577, Japan; Laboratory of Molecular Pharmacokinetics, College of Pharmaceut…
Förderung
- Ministry of Education, Culture, Sports, Science and Technology
- Ritsumeikan University
- Japan Agency for Medical Research and Development
- RIKEN
- Promotion and Mutual Aid Corporation for Private Schools of Japan
- Japan Society for the Promotion of Science
Zitieren
APA
Watanabe, K., Negoro, R., & Fujita, T. (2023). 5-ALA treatment increases intracellular heme levels and enhances CYP3A4 activity in genome-edited Caco-2 cells. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2023.04.077
Vancouver
Watanabe K, Negoro R, Fujita T. 5-ALA treatment increases intracellular heme levels and enhances CYP3A4 activity in genome-edited Caco-2 cells. Biochemical and Biophysical Research Communications. 2023. doi:10.1016/j.bbrc.2023.04.077
BibTeX
@article{Watanabe2023,
author = {Watanabe, Keita and Negoro, Ryosuke and Fujita, Takuya},
title = {5-ALA treatment increases intracellular heme levels and enhances CYP3A4 activity in genome-edited Caco-2 cells},
journal = {Biochemical and Biophysical Research Communications},
year = {2023},
doi = {10.1016/j.bbrc.2023.04.077}
}
EUVIMED